Citizens JMP raised the firm’s price target on BeiGene (ONC) to $348 from $288 and keeps an Outperform rating on the shares. BeiGene’s Q4 results beat top-line estimates due to $828M in Brukinsa sales globally, an the company forecast total revenue for 2025 well ahead of the firm’s estimate, the analyst tells investors in a research note. BeiGene shares represent a unique investment opportunity to own a growing global biotech, with 41% potential downside and 34% potential upside, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene’s Strong Financial Performance and Strategic Positioning Earns Buy Rating
- BeiGene Faces Potential Tax Risks Amid Corporate Restructuring: Stakeholders Urged to Review SEC Filings
- BeiGene Reports Strong 2024 Financial Growth and Strategic Advancements
- BeiGene’s Earnings Call: Strong Growth and Market Leadership
- BeiGene sees FY25 revenue $4.9B-$5.3B, consensus $4.74B